Ensysce Biosciences Balance Sheet Health
Financial Health criteria checks 3/6
Ensysce Biosciences has a total shareholder equity of $6.6M and total debt of $387.2K, which brings its debt-to-equity ratio to 5.9%. Its total assets and total liabilities are $9.4M and $2.8M respectively.
Key information
5.9%
Debt to equity ratio
US$387.18k
Debt
| Interest coverage ratio | n/a |
| Cash | US$4.15m |
| Equity | US$6.58m |
| Total liabilities | US$2.80m |
| Total assets | US$9.38m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: ENSC's short term assets ($9.1M) exceed its short term liabilities ($2.8M).
Long Term Liabilities: ENSC's short term assets ($9.1M) exceed its long term liabilities ($3.2K).
Debt to Equity History and Analysis
Debt Level: ENSC has more cash than its total debt.
Reducing Debt: Insufficient data to determine if ENSC's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ENSC has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ENSC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 27.9% each year